

Statistical analysis title	Cohort 1, ACP: Fesoterodine 4 mg
Statistical analysis description	P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline bladder volume at first IDC and baseline weight.
Comparison groups	Cohort 1, Active Comparator Phase: Fesoterodine 4 mg
Number of subjects included in analysis	26
Analysis specification	Pre-specified
Analysis type	Superiority
P-value	= 0.0336
Method	ANCOVA
Confidence interval	
Statistical analysis title	Cohort 1, ACP: Fesoterodine 8 mg
Statistical analysis description	P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline bladder volume at first IDC and baseline weight.
Comparison groups	Cohort 1, Active Comparator Phase: Fesoterodine 8 mg
Number of subjects included in analysis	36

Analysis specification	Pre-specified
Analysis type	Superiority
P-value	= 0.0327
Method	ANCOVA
Confidence interval	
Statistical analysis title	Cohort 1, ACP: Oxybutynin
Statistical analysis description	P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline bladder volume at first IDC and baseline weight.
Comparison groups	Cohort 1, Active Comparator Phase: Oxybutynin
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	Superiority
P-value	= 0.0017
Method	ANCOVA
Confidence interval	

